88% af de patienter, der blev behandlet med Pegasys oplevede uønskede hændelser sammenlignet med 53% af patienterne i sammenligningsgruppen behandlet med lamivudin.
Adverse events or laboratory abnormalities led to 5% of patients withdrawing from Pegasys treatment, while less than 1% of patients withdrew from lamivudine treatment for these reasons.